New approaches to front-line therapy in multiple myeloma patients aged over 60 years
J.F. San-Miguel, M.V. Mateos
Hospital ClÃnico Universitario de Salamanca, Centro de Investigación del Cáncer, Universidad de Salamanca, Salamanca, Spain
High dose therapy followed by autologous stem cell support (ASCT) represents the standard of care for younger myeloma patients. However, half of MM patients are >70 years at diagnosis and other have comorbidetes which preclude ASCT. For more than 30 years Melphalan-Prednisone (MP) has been the standard treatment for elderly MM patients, although the response rate (RR) is only 40-50% and complete responses (CR) are rare. Median duration of response to MP is 1.5 years and median O.S is 2-3 years.
[>Read full article in PDF]